Phase 1 Expansion Study of an Oral TORC1/TORC2 Kinase Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)

#869

Introduction: Clinical efficacy of everolimus, an allosteric TORC1-selective inhibitor, has been established in pancreatic NET. CC-223 is an ATP-competitive inhibitor of the mTOR kinase, inhibiting both TORC1 and TORC2.

Aim(s): To evaluate clinical activity of CC-223 in NET.

Materials and methods: After establishing MTD, subjects with non-pancreatic NET on somatostatin analogues (SSA) and progressing within 12 months were enrolled in an expansion cohort of CC-223 at 45mg QD in 28-day cycles.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Meyer T, Mahipal A, Bendell J, Nemunaitis J, Mita M,

Keywords: TORC-1 CC-223,